TCGA-E9-A1RE-01A-11R-A157-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 47
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.440
- MYC_TARGETS_V2+0.420
- E2F_TARGETS+0.370
- ESTROGEN_RESPONSE_EARLY+0.350
- G2M_CHECKPOINT+0.330
- MYC_TARGETS_V1+0.330
- OXIDATIVE_PHOSPHORYLATION+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.300
- MITOTIC_SPINDLE+0.210
- DNA_REPAIR+0.190
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.520
- TNFA_SIGNALING_VIA_NFKB-0.480
- ALLOGRAFT_REJECTION-0.470
- IL6_JAK_STAT3_SIGNALING-0.450
- INFLAMMATORY_RESPONSE-0.430
- KRAS_SIGNALING_UP-0.380
- COAGULATION-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- KRAS_SIGNALING_DN-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-69-7973-01A-11R-2187-07 | — | cohortA3 | 0.895 |
| 2 | TCGA-AN-A0FW-01A-11R-A034-07 | — | B | 0.880 |
| 3 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.880 |
| 4 | 20120289.LumB | — | B | 0.878 |
| 5 | TCGA-EW-A6SA-01A-21R-A32P-07 | — | B | 0.875 |
| 6 | TCGA-BH-A0H0-01A-11R-A056-07 | — | B | 0.872 |
| 7 | TCGA-E2-A1IE-01A-11R-A13Q-07 | — | B | 0.871 |
| 8 | TCGA-2F-A9KP-01A-11R-A38B-07 | — | — | 0.869 |
| 9 | MBCProject_0343_T2_RNA | — | B | 0.868 |
| 10 | SRR8942974 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |